Edition:
India

Savara Inc (SVRA.OQ)

SVRA.OQ on NASDAQ Stock Exchange Global Select Market

9.17USD
20 Apr 2018
Change (% chg)

$0.04 (+0.44%)
Prev Close
$9.13
Open
$9.13
Day's High
$9.32
Day's Low
$9.07
Volume
18,197
Avg. Vol
56,588
52-wk High
$17.11
52-wk Low
$4.63

Select another date:

Thu, Mar 15 2018

BRIEF-Savara Reports Q4 Loss Per Share $0.23

* SAVARA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Savara Initiates Phase 2A Clinical Study Of Molgradex For The Treatment Of Ntm Lung Infection

* SAVARA INITIATES PHASE 2A CLINICAL STUDY OF MOLGRADEX FOR THE TREATMENT OF NTM LUNG INFECTION Source text for Eikon: Further company coverage:

BRIEF-Savara Announces IND Approval For Expansion Of Molgradex Phase 3 Study Into U.S.

* SAVARA ANNOUNCES IND APPROVAL FOR EXPANSION OF MOLGRADEX PHASE 3 STUDY INTO U.S.

BRIEF-Savara ‍Received $5 Mln Award For Development Of Aerovanc​

* SAVARA INC - ‍RECEIVED $5 MILLION AWARD FROM CYSTIC FIBROSIS FOUNDATION THERAPEUTICS FOR DEVELOPMENT OF AEROVANC​ Source text for Eikon: Further company coverage:

BRIEF-Savara posts Q3 loss per share $0.28

* Savara reports third quarter 2017 financial results and provides business update

BRIEF-SAVARA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

* SAVARA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Savara announces proposed public offering of common stock

* Savara announces proposed public offering of common stock Source text for Eikon: Further company coverage:

BRIEF-Savara expands molgradex development to include treatment of nontuberculous mycobacterial (NTM) lung infection

* Savara announces expansion of molgradex development to include treatment of nontuberculous mycobacterial (NTM) lung infection

Select another date: